DENDREON PHARMACEUTICALS LLC.

Company Overview

Dendreon operates as a commercial-stage biopharmaceutical company and offers manufacturing services for the cell therapy sector. In 2001, Dendreon was awarded U.S. patent (No. 6,210,662) for the composition of sipuleucel-T, a cellular therapy for prostate cancer. In 2010, Dendreon received FDA approval for sipuleucel-T (Provenge), the first FDA-approved immunotherapy derived from a patient's own immune cells. In 2014 the National Comprehensive Cancer Network recommended Provenge for first-line use in patients with M1 CRPC.

In 2017, Sanpower Group, a private Chinese conglomerate, acquired Dendreon from an affiliate of Valeant Pharmaceuticals International Inc. for $819.9 million in cash. One year later, it resold Dendreon to Nanjing Cenbest, one of China’s largest retailers, which had recently branched out into healthcare.

Company's Business Segments

• Cell Therapy : The company provides end-to-end manufacturing services and regulatory expertise to commercialize new treatments across the cell therapy market.